<SEC-DOCUMENT>0001193125-13-238319.txt : 20130529
<SEC-HEADER>0001193125-13-238319.hdr.sgml : 20130529
<ACCEPTANCE-DATETIME>20130529062458
ACCESSION NUMBER:		0001193125-13-238319
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130529
FILED AS OF DATE:		20130529
DATE AS OF CHANGE:		20130529

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		13876647

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d545866d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Form 6-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>UNDER THE SECURITIES EXCHANGE ACT OF
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the month of May, 2013 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Novogen Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Translation of registrant&#146;s name into English) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1-7 Waterloo
Road, Macquarie Park, NSW, Australia </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive office) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form
20-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper
of a Form 6-K if submitted solely to provide an attached annual report to security holders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Note</B>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and
make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of
a Form 6-K submission or other Commission filing on EDGAR. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant by furnishing the
information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </FONT></P>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Novogen Limited</B> (Registrant)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Andrew Bursill</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Andrew Bursill</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Secretary</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date 29&nbsp;May 2013 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g545866tx_logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASX RELEASE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>29&nbsp;May 2013 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Novogen Announces SPP Outcome </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novogen today announced the raising of $789,685 through the issue of 4,645,207 shares to current Australian and New Zealand Novogen shareholders under a
Share Purchase Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr Graham Kelly, CEO, said, &#147;I am delighted that so many shareholders continue to have enough faith in the Company
to subscribe to this share offering. These funds, combined with the $2.4M we raised through a recent placement, give us sufficient funds to continue with our R&amp;D program for CS-6 with the goal of bringing it into the clinic within 12 months as a
treatment for late-stage glioblastoma (brain cancer) and ovarian cancer.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Two other candidate compounds have been identified, and
their development will depend on raising additional capital when we feel that market conditions are appropriate. Our long-term goal is to be the pre-eminent company globally in the area of personalised chemotherapy for many cancers. For that, we
need a range of drugs that are active against both differentiated and undifferentiated (stem) cancer cells. Attaining that goal will depend on accelerating the development of those two new compounds along with screening the new libraries of
super-benzopyran drugs currently under development in Switzerland,&#146; Kelly added. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Novogen </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol &#145;NRT&#146;) and NASDAQ
(symbol &#145;NVGN&#146;). The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on comprehensive anti-cancer activity against both cancer cells and cancer stem cells. The
Company&#146;s inaugural drug candidate is CS-6. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About CS-6 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">CS-6 belongs to a new class of drug candidates intended to treat most forms of cancer in a comprehensive manner, targeting both cancer cells and their progenitor cells, cancer stem cells. CS-6 shows broad
anti-proliferative and cytotoxic activity against human cancer cells and ovarian cancer stem cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being
developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Further information </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Contact Dr Graham Kelly, Chief Executive Officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 61 2 9476 0344 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 61 2 9476 0388 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mobile: (61)&nbsp;0429 854
390 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">16-20 Edgeworth David Ave Hornsby NSW 2077 AUSTRALIA </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">PO Box 2333 Hornsby Westfield NSW 1635 AUSTRALIA </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">E: <U>Graham.Kelly@novogen.com</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further information is available on the Company&#146;s web site, <U>www.novogen.com</U> </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g545866tx_logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASX RELEASE </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>29&nbsp;May 2013 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Novogen CEO to speak at Investor Forum </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Novogen CEO, Dr Graham Kelly, will be presenting at the &#145;Stars in 2013&#146; Investor Forum in Sydney on Tuesday 4</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> of June 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The details of the Forum and a copy of the presentation are contained on the Company&#146;s website <U>www.novogen.com</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novogen also wishes to draw attention to the fact that the website has been modified to cater for the anticipated increase in news flow stemming from the
Company&#146;s expanded R&amp;D programs. Of particular interest, the medium-term objectives of the Company are now detailed in the Novogen Blue-Print. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Shareholders and other interested parties also are invited on the website to register for an E-news alert facility. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About Novogen </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novogen Ltd is a public Australian biotechnology company whose shares trade
on both the Australian Stock Exchange (symbol &#145;NRT&#146;) and NASDAQ (symbol &#145;NVGN&#146;). The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on comprehensive
anti-cancer activity against both cancer cells and cancer stem cells. The Company&#146;s inaugural drug candidate is CS-6. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About CS-6
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">CS-6 belongs to a new class of drug candidates intended to treat most forms of cancer in a comprehensive manner, targeting both cancer
cells and their progenitor cells, cancer stem cells. CS-6 shows broad anti-proliferative and cytotoxic activity against human cancer cells and ovarian cancer stem cells. CS-6 also has been designed deliberately to meet the major known criteria for
crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Further information </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Contact Dr Graham Kelly, Chief Executive Officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 61 2 9476 0344 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 61 2 9476 0388 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mobile: (61)&nbsp;0429 854
390 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">16-20 Edgeworth David Ave Hornsby NSW 2077 AUSTRALIA </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">PO Box 2333 Hornsby Westfield NSW 1635 AUSTRALIA </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">E: <U>Graham.Kelly@novogen.com</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further information is available on the Company&#146;s web site, <U>www.novogen.com</U> </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g545866tx_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g545866tx_logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*@"7`P$1``(1`0,1`?_$`+X````&`P$!`0``````
M```````&!P@)"@$#!`(%"P$```<!`0$```````````````$#!`4&!P@""1``
M``4"`P0%"`@#!P4``````0(#!`4&!P`1""$Q$@DR$S,4-4%1<2)B-!4V\&&!
MP5(C9#>A8Q;1X?%"<D07HE-594<1``$"!`,%!@,%!08'`0````$"`P`1!`4A
M,09!41(R!V%Q@2(3,T(T")&AP105L6(C-1;P4H)#1"71X7*BPO*$-O_:``P#
M`0`"$0,1`#\`O\8$"!@0(&!`@8$"-:O0'R?7EGZ-GIQY69)G!@%1D,(;72E]
MH"9U+W:TZKN6C6LJ$HFV5T&$?UJ2;R8HBN#5%!N)9-(Y@4<$B:FIE5NN)`$$
M@<H<0AQAARMA8ITNC%)^Z(2GO5*]>'[*I7#5(2%IRQ3(3`WXGOARQ1$?I]-^
M$.[.)G&<]D>L"#@8$"!@0(&!`@8$"!@0(&!`@8$"!@0(&!`@8$"!@0(T"KMR
M`Q<_LVAY,MNW!9X#.$_40H\(,CLGMCV)Q#(=^>7F#[]^#`.TXB%`1/A49']L
M>@,`^7;EGEY?3_#`[1E!$@&4\8!C`4,Q$`](@'TRP8$X.1EY<XY3K")#"(E]
M4VX`'=D/G`-^"*209B$GBXTV2L8_NS/VX814"Y[%Y;QZ*N9/I+U=V9D6T;/+
MV/D*:68O4U30M9Q5+5T]7JNBZK224(+R%GHFI6A1`F2K95(BZ8@HF0<6_3=&
MW74SM.[C-)'<<P1]V,<P]8;Y7Z,UO;]2TADTMF1PF#LD1A.+$6@K7;:'7O8Z
M,N[;!T>.DVSA&$N+;^2704J*W=9=V(X=04H!!(5XQ<$S6CWR900?-3`<F1@4
M3)7;K0/VRHX""6R8V_1>M*#5]I174V#H`"T[>+L&Z'S9[!$-O\<,HND:.L,.
MXQ!'?D`@(E`1W;!V[AVX]`#;"142#Z:@H\6'=&3'.`;!`HAGO#8.6>>W;E@D
MYR(A0DY($SVS`_9&2*<0!F(9B&[,/\?)YL&1+"/()!X5%/'N$;0'/;LR^F>"
M,>^_.-1CB4P@`E'8'J^7RCGZ,L&`"(+S[@!O,XR4_2XS%SSW;`$`RW#MP2I8
M`9R@3($U"0_;&1/[10].7]N/*0J9!$X`/$)IG+[8QQY;S%^K++Z_..W=CUWB
M4$K#,R[Q&#*9<.0AM#ZM^?IP0Q$CS0%*2GRJ,IY'9W1D3&``V9YCY`W;=P[<
M>%<8,L)P8G/A)\=D8!4!`1`Q<P`<PS\H`(X.2N0$>I'A+K:IK!_AB*^VLWFI
MWDTE:]"VD<4A351Z::/I"V597:DVD1**5[3=,5H__IZ4J=K*)S!6'=(29D&1
MNJ%F<5>+JA,!E"CBF7+4[ENOJ:%;:33$3*L>(?A]T=5]-NA=@UMTH5?EU:V=
M8.O.M4:%E`9=6WCPJF.+B4`0)*SB>2G:DAJMAH>IJ>DF\U3\_&1TS!R\<J59
ME)Q,NBB[CG[10AC$51<M5BG`X#T38ME.\S6,&H8*BVL2^R.7+E1U5LJUT=:R
MM%2PZ4*2<PH'A4".PX]T1_\`+PU67.U4M=3[JY#2EF)K/:EJ[M%204JP?1Q5
MZ3IDZ)8]::[Y(O\`O<TIQ_FJI=4F8,LB!B/M->NL+B%"3:%2G&C]3=$T6BGK
M8BD=4ZS76UFJ43(J27`J:!(`2!&$\81S5)S#KL$U`J:+M"UKHF]>HV/CPD;B
MU353YRRM=9M@HDW6*>IG3)5,[V3;HO$SK)"LB1$54TP!=<PHE9W&[5JJH4-E
M2VX\02HJGA+N(BWZ/Z3VG^DT]0>I-6Y0:0?444R6I?F'UC8`?A[0,L<LTZKR
MMN=+IZII2Z]21NEK4Y25/MC3-=VMMI!U72%<L8AN4%I,:5>NOS)U5@W`YQX$
MUG!@*/`W4RX<,I:J9!J7@VIM.)3-4I;=OC$Q:K9]/^J*UO3MO:N=EJGE^DBJ
M><#C*E*P2MP*F$I)PV9Q&/SGJUMYS#N6_976]95K)**V+NFYIVY-//DTSU%0
M#"XC%A!5+!U"")NK`D3536$61<$S17:N2K%R`Y@#2.GE^HZ]:BTN29\)W\7_
M``CB3ZP^E-^T8S^EW1GC=HSQMOI]IYE1\KB#M"AVX'"()>6/KHJK0/J@I.YZ
M3QZO:ZJ73&D;X4JDNH+2=H&0=ID-.IMA.5`]140X6^)1ZVQ3A(LAQ=6N<IM%
MU!;$U=+QH$U2SCC;IMKEW1VH6WGEJ-N40E:/AQ(!\1^V/TM25;`FI<*T)+LU
MZ7/!%J=.<;N...5I\8PLN240<`8Q%62D:(+%/GPB0<\9&]-I2FS[B,YQ]$K=
M_N2F$TWG54E`;EC/U.7[8BOTL\P6;K#2C?;6YJ05IZB;$P-R:X2LT6!B)!K/
M2UK:6EO@$*O(D>2[L*@JJJIT.Z-2($;IG62$`*!3"):Y1ZA;_3U72H3*D$^'
MME^V-OU3TI6QKVW].=(@U&I'6&DO!4BE#KB05&8R0V)DSRA%[6:A>;%K7C0N
MW8&D+":6[!S8N%K=K7N8S=;7!K2(35,1E/*L8XB;=C&R?!F4X())"`B*`N$^
M%8\?3W*^7P^O1(2TSF"9Y;-NZ+1?-)=#NES_`/36K7:R]:F9(_-&F>DPDG8V
MH2/$DX$%1`W"#!;GF#:E]/=^Z'TT\QZVU%4BYNI(DB;1:CK5N7XVIJR8.X2;
M(PDXQDCG4A'BJ[A)$Z@G0.@HLGUC<J1P7PZ3?:FBKD6NZH2'ECRJ3.1[YDPT
MNG232.K-*5>L.D52M\6]*E5%O<(-4R@8\:3(%:`,R9DRSG$GVHS4C;72Q9VK
MKU7<F#0U'T<S*LN#=/O$K-2SDW41%.P+(5$QD)F;?"5%NGF`<0B<XE3(8P3=
M?7LVVC5751`:"3AMXM@\8Q?1FD;_`*ZU!1:9L#*G[K6+`)&"&T@`K6X?A2@9
MGLWQ%K1-Y><'JRC&-T[04)IXTGV?J1(DC0T;>TD_6UR:@@%RBO&3<E&Q:14(
MU&5;G(H1,Z340(8#%`Y1`XUQM_4=T:16TJ6FF5IF`>*??GMC;ZVQ=!=!U3EG
MU*NXW^]LJ*'?RJPVRA0P(2H2GPF<\29YPZK2Q4',L97.F:+UBTAI^F+=ITRX
MEH*[MG969:+KU`G(M6K6EGM*RA2N#'<M%57!U^J0(B5'(#*&-PXDK<B\H=`K
M_3,\BF>7B8SW7C/2PVM-?H%=<BI4J2J>HD>#N5+B/>#*$KUV:I-7%O=56E_3
M%I22LL%07ZI"XLXH_O)'5$YBF[^B"HO>K!_3[]-TS06C$E@``:KB=829B4,Q
MPE<ZNZMW)NDMR6U)6%%1492E*4HL'3G0^AKMHF\:NULJX);MK[#:!3!)'\4R
M/%Q;=W='T*'3YS/];T:%QI'0J:WX5+#'KD*5)<_^IS4>600_J$M/]\;D8_&S
MQ76@U%4>J!;AXO5SPM3#4JG@FH13!F>)F2>R4CGWQ&7H]#&J%UNS*O(N_#Y`
M\&_3,\A@)C'?L@L\UC6YJ)T>):=FNGFEZ/K&H[LU36D.^@ZIAY:8=2:5+0D=
M-MV$$$5+Q*K=\Z;*+\0B"YA``X"&,`%,QU/=:FUIIT4R4KJW5Y&<L!C*6.4]
ML6+H3TUTCU!-U&LJURWL4;:2TI/"4\3BE)27%$$`3"=V9A_6E34C16K&QEO[
MY6_<B:!K.'17?1:JY57]+U&R#NU14O+]68>&1A),AT39Y<9>$X>J<HC/45PI
M;A1HJ6E$D8$#,*&8C*-<:2N6A]15&GKCPE3:R4+'*MDXI<2=H4G(Y3ALE"ZL
M+HU'S/KUZ0'S.E"VIM[86D+F0KUO'/TZL/.SPP)7:;Z3-)G8+QP?%C@1(K4A
MPR+F<<ASBF;P%:G=MH!X`P%3VSBY7'I_;*3HW;^H*%.>M55SS!3AP2;,IC"<
MY3GC#**AMS25W.=S?VV->0[>=HRNM`;2FJDB7)2F3>1DG)0C9<"B8INI<(F,
M51%4`XDEB%.4>(H8B7:5NLU6XPX`4EGOEE&G4]VK[']-MKN-"YZ=4UJ)2D+`
M\P4GB,P9Y$`@C:(.?+8N#5NER\5P.5S?*;=2$E;=5S6VE>LY54Z9[BV0D'*S
MX(%LHI^6M)TJ4>,&Z8B9-,'"8!P-L\.[)5N6FI-IJ%32I<FYB7%Q3GW<(D8A
M.J]LMFK=.T?6G3J"&*Q/I5S8\P;JR`DKV2"R#F.V9CNY-"BB4#KY<(%$QD]<
MUXEB)[,SBF*"B:7E`#*#D'U9X]:9=4Y^=941Q(JUI)W2$_PAKUUHVVKOINEE
MPG]!I0L\4P2KCFKLE/`04N1%"LZAH75S>^<`'=S[E:J:]CZRE7ANNENXP"@2
M$7&'6,8RA&B+VH'2F6>1C#EEZA0!IHSA=5652S-[UBGN$_QB>^I]8I:O3NFZ
M4*%CI;$PMM`)2@K<YW0!@29">[?$\C@I$T3'+D!RF`0$XF$#"`YY=,0$=FS%
MYXB?*OD.'VQRPAB1XV#YP=BE$#?,$[IR[917+T@V;M_4FN#G$Z-W\.VEM/MQ
MV%/2%04XQ`R45"S%:)/`FF,<4A>[Q\HT6J5=1$Y<C)*LTS%#\L,J/I=7Z?JF
MM8I044C9GGMGG^'C'3_7VAI=8=!-&W:[?Q:MRE>H5I)FM24XMN$?W00#.9BH
MAKDT;7.T-:@*ML;<QNX<MX]9>0M_60M#)1%R;?.G2I(6JHM3UFPNA3R0DFQ!
M$S-^11,VS@,;I>Q5Z+E3!I1`,N^/B-KO1UPTC?'[8IH^BXHK0O)(3F!/NRBS
MA:36=6%7\AFV5(4](.9&^EPJC3T&TF4BXFEG4DM/&I]HZ1R'KESL+6/&Q1,&
MTISE'?MQBO47U;<7*9G"HJ5\(5+E!/-+;]HCZ9?1@&M65-)?;GYK19:=;SA.
MZG1Q)"MV.`E/*%PYHEGH:SFESEJ:,D'2<7:1_?VU%OKAO$LV[>0;4_',FSU]
M(JE,FV.:5DYE\]4!0P"=80.`YE'%(OS2J.FMUKRHRL<9EG_:<=2]%;X;UK/6
M&O1-5\_2JERF5B2A3I($NY`D#A*+&L3%1D.Q8144T:L8V,8,HUA'LTBMVC*/
M8(IMV+5JW3$"-T&S8A2$*`9%*``&[&@I0EI(:9`2Q(##=*4<EO5+JGU*>XY*
M4HE2AQ%2E$DDK)F9G?$1O/)H:F*BY>EU:CET$?C=O:AH.MJ,D0$B3R*J9*J8
MV#*HS7,;K$SNXR5715*02BH40\H`(5+6B4M6%RLP%0RH%"Y8C$8?V,="?2N[
M5#J[0VEM7#3U33S;GPH6DH)DX?C`ED1MAFNO>;D+S*<E2W-TNM&A;R5Y;BJ;
MF-GRBAVM13B5.V^[O&RQ1'JE^\GFW9<U.(`[T(B`[<15^4JJ1:$56"'W4<>Y
M7E!B^=+F4:</4.^V.2;S14;S3!29!L..K"E(EB0`)82RSBR,V:HI-2%30*@F
M@`D11('5E321]1))(A=A$R%#(I=@%#9NQH"6T!7`3Y9R2!D!LRCCA:2MT@XN
M%7F42<3/%6!Q)G.9.,)*O?VT36]+33RO6D02]#ZD5*^94`?OHS3BC4'`M%JA
M3$&HL2M$W!1(.:H'S\F$U5#2'5,)/\4`*EV9?9$H-/7E5G-^0P?TI+Q:4YQ8
M!<]QF<0`?&(8>916=R+>\S3E\5?:2U;B]-PH>W-\1IZV;.H8VEEZC%ZS[H^*
M6>EBC'L`81RRKG\S8IU/"7UA#%,OBZIK45,:9KU@$*)\2,,.Z.GNC%ITW?.D
M.J*34MP7;K<JII27@VIQ*3,8J`W;-\/TT[ZE=9=S[G-:4O?H3E]/E"+0DL^<
M7$?W>H^LT6THR!`8V)^"P:0/C&ECG.`*]`G5YCOQ,45?6NU,JBF4V!A/$9X>
M/=A&1ZOTET\LMI-9I[4*;K7>JE(0*=38*<,25G9V0U[F>`)]7G*.2,`"4VJB
M8`!'(P*@,;`ER-O+D(!MQ&WPI7=[93J$^-U0G_=EM[<#V1>.CO$WT[UT^KA2
MX+8R`)3$E.SX@,PH93GOWPF\`J?E:Z_W-'.3C%:)->%4*2%(+FR1I^S>HMP9
M)-W"J&,(-HF$JI10I"]$O4K(B&169\)I1_3EU<7/_;JE1`&0;7]\^(X;)3GC
M$I5(3UJZ7.7)E*5:[TM2I2^1BNHH4Y*E@2I`Q,ISD=\'.T:J@\]_50=1/A..
MD"W(E2+F.905HT2%-Y?6*`85I5C^KWY`%S\HDD[LH3OK@5]+5F0`K\DW?*A.
M7FFL<1PW@3$HZ*5CY0O/IN9*GC),L6IHH@VY9,6#LL8HL$[3PBW2DQ1!B9R7
MA$13!03Y`.S9A6F0\=6J>X2&U-$8]D15RNU$KZ9K?:T.)-Q3?5N%OXP)*`)[
M,86GF?Z6*NNO;JCM05A16B]5.E2:&YEII2.)D_J6.CS(O:IM\[X!)WY"<8-!
M.@B?,JBY!1'U%U,W&H+<NHI_SU+)-PIW2M!V89CQ&40W176MIL]ZJ-):O4/Z
M$O$V7P<4M+4#Z;J1L4%'$@3EW0V?D(51(US9W557DG#JP;VNM5565HYBUD72
M!6#VHX*(F'K-`7J#9<Z+5P\%,HF(!@`N0[0Q#Z%-0_;ZEYY"D5+E4HJGMGM'
MWQ<_JKH;1:=4V.VVBJ14TC5D93ZJ#,%*5+X9[E2E,0GLNPO%RC=5EX;GTY;*
ML;O:$]3%0GK:L$+=13JH*GL?7SAPY=/7Z\&U*)C1(KOUP*IF1!TR%-,5$EVQ
M2KDI*]+W1^N?2K]&?*>4%12K9,#8>R'S-38>N^AZ*TW2M9I-?6=L,L*<(2FJ
MIQDB?]X$8DY=HS7FY'.UT]RE*&A-*5,72U+7TGD#-:0MS35LJVCT8^<=%429
M#6KZ3AV?<6#5R&:Q&P.#'X<@,4HF4*\K-86VJ0*>UA]VM5+A2&U)F9S,R0`,
M`8KMH^FO5K5:FMUP[16C332N);HJ&U%;8Q\J4DDE0P$\B9F%:Y6>CZY.GNB+
MEW<U#O4GVIK4_6?_`"+=4B2B+DM-(=8[<0E'B[;'5:J.F2TDX7=%1.9%%14K
M<AC%0`YG5@H7J0O55>0'JE8(&,QV'MBO]:NHMFUC<J*Q:.;]#1=DIS3,)PFM
M1`#CI.TJ(P_YPNFOW0-9_7[923M7<QF6,GHI-U,VMN6P:IJ51;:LC-E$D)6,
M7$`.ZA7YNK2E(TY@0?-R^MPJ%253NMOKG[>YQ,F28YBUCHRVZQM"K7<$S,B4
MK^,'&0GNGG%9?DV:4;T06N*H],]\8A-"F-`MPZSO)+18'.K$.[L7%IVFJ/H2
MHH\RA@3=1$U!4ZG,1(]60W4D.8<CF$`\:Q+=XO='5)^42U(@X^;?NBP_3W6+
MT!T@U!IM^;6IZVZ!N61_+(09@'.2]NPQ9.YE6D!76CIDGK:0#\L'<BF)F.N-
M::>46.V3CZ^I@BYXYLZ=I$55:1LPS=KM%52E,*!E2*Y&ZOA&M7^V+N=`D-%/
MJ(,P<8UOI'KT]/=8,79]/'9ZAI5/4I$O8<'"K`R\PS!/;#(K#\WZG;4T\UM=
MS%*'N7IVOY1$<C3\[+RENJHEZ)N*K&)`B-34[)T\SEDRN)<$0.J0@*LSJG`Z
M"YB&`I(NWZ@%.UZ5S2MM;8"<1S<.$QWYQHNI>@=3=*C]<Z9UM-<M&51XDA=0
MRAQI:\?34E2@1P$RG+9XPB%\;D70YS-<T386Q=O:_H/0[2]9P]87KOI7U.R%
M(?\`(Z<&Z,JQIFBXY\4CEZ@8!.""6TYG*A7+D$4T$R+LZUQ_4]0:9E)_1I#B
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M-8DY!"E`I.1F`1%UU!]/U3=B;STSJZ.XV"H5QM)+[:'FP3/A6E:AE.6SMA-[
M!7YHW5[SBH2_UC8NNJAM!3VE"HJ"DJZFJ!JBEX%*HRSA'1&B;Z:CFK<YG23D
M@H`)B&5]82E-PCD=LNE)=]0JJ*3U#2EC@)4DI`7,G)4IX$8B)#5>E*C0G1(:
M<U`_3#4=1=/5#33J7#Z?"D3)3@#,$$=D&OF-W3IRQ7,JT"7MKIC5RMO:$MY>
ML*D?TK2%0U@[8FFF?P:.3^'4\Q?.C*.9!\D7(`Z`F-N*.$=05--0Z@I:BK=?
M;0$*`]-!4%2*9SD#*6SO,(=(K16:FZ1:AL-M%.BOJ:FGX2Z\ELC@FHX$^:?#
MG(R,M\.EIOG!Z,JMJ*GZ8B7E[/C%33D13D:+W3_=)DQ&1G9!M%QY'CYQ3Y&[
M)J+MT7C74$J:1,S&$`#/$Q3ZKM554"D:+RE3!\R"D#[0)^$4>IZ%=0*"C<KZ
MD4*Z2G25F52R#(#,#BQ[A.$PYEL?(R&KOE,*M8Y^]:QVJ657>JL&3MTC'HC&
M0>:[]9!)5)FWV;#JF(4?/A*]L*-TM]0TDJ])]4Y;EC"7=+'[HF>DM2Q2].]:
M?G74)KEVQI*`2)+479E`&94`#CD(?EK+TLT5J_T^5]9&KRE;*5`R%Y2-1%2Z
MV0HNNHT%%Z4JB-6`!715C9/A*N"9@%5H=5,1`##B7N5$Q<:9RE>$R#Q`_O9I
M/@<XS#I[K2Z:#U73W^B,FDJ`?;/*[3K\JVW!D?+.4\,HK::'SZJK@ZK=<M%5
MPVEX35=2_+XKJP,?.KBLU<25S*'CF%'4%5A)19$C8Z\JJ,<[(Z(8Q5=BX"(*
M&X<WL:;LJ]5Q?216?E5-A1R)`/"1MS`CM#J17]/Z/I[I>ZV53:M*NZG36O4\
MP2$+=0X\@C*02%IED`91;>-XDKX;[NGN\1[0-W\C\7V8U-'SWPY'+..%?]$C
MW_<V^UX?O1WN=Q.AVI>EZ3=G[?W857D<HKSF:,OFMN?AV[H)U$^[2?R5[XI\
ME^Y=%+Q+_P!CY_9Q'4?,>3G^#\8L&H,U_-\J?F.;+X/W(-CWL5^R[-3=T.Q_
MW7Z?\7LXFQD>7+XLHBZ3YRGRY3EX?]V[MA);<^*RW[+;P_;/QGM%O'O:\_M\
M6&=/\7)_ASBR7CY4_P`QR'NY9_!V?A"S(_Y.P[0.CN[0W1]K[\!_G3RYC//P
M[8K/^4GEYAER_P#M':KT%-W1-NW[A_ZO-@+Y#W&/:N4YY;,_#MW0DE/_`#[7
M'[<=C3'@'[B>%K?N+_+_`/$?I./'E7RJ.;(9_P#C^,-%_P`Q3R;<N;D^+MW>
M,*D;<;[.GT-P;_O^S"S'MB/7^8]W;>6$>NAX=%?M-VW_`-:]RZ1?"OU'W98K
M]Y]]/RN7QQ/V/_Z^4?+\F6SMWP?:>\#C/!?=F_R_X#N2\,_1?]OV<L/K+R+]
MK/X,O#LB/K_YE_JLC[O/X_C'V@]W/V>Y7LO]8;OK\^)9.6S/PVPRI?F$^U\7
M+RYGF[=_;"2W/\)9_M3[V;]T_"]X>%_JO/\`;AJ.<^U$_I;YEW^9<RO8R\.R
M#E1G@;3Y.Z*?R7\O]/\`VOL??A-?,.3/9'BZ_,CYKW#[O-EM@Q.MYO<>@':]
M+R;_`&/PX<-YCDV9YPRH_A]SF5W9[/QC@/O3\#W^3I=(O\?ORPTK?>;]CF//
MGELB17F/F\E?]&7Q=D8D.V:>Y]J'O';;P]R_F_W85<]]'+X_A$-:_<J/>Y4^
MW[7^/LW>,?73[,.CT`Z?I-O]KS?7A=?S)CQ5^^_E[8_MW018OYZG/DKW!/P[
HYT[%'QK]-^#V>##4?.GV\]F?C$Y5_P#YNG^:S//\OD?;_>W]DX__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
